(VERU) – Globe Newswire
-
Veru Announces Date of 2024 Annual Meeting of Shareholders
-
Veru Reschedules Annual Meeting of Shareholders
-
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
-
Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q
-
Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss
-
Veru Reports Fiscal 2024 First Quarter Financial Highlights
-
Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs
-
Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
-
Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024
-
Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss
-
Veru to Host Investor Call on January 4th, 2024 to Discuss Recent Financing and Strategy to Prioritize the Development of Enobosarm as a Combination Treatment to Prevent Muscle Loss and Augment Fat Lo
-
Veru Announces Pricing of Public Offering of Common Stock
-
Veru Announces Proposed Public Offering of Common Stock
-
Veru Reports Muscle Data from 5 Clinical Studies of Enobosarm that Support the Advancement of Enobosarm in Combination with Weight-Loss GLP-1 Drugs, Ozempic®, Wegovy®, or Mounjaro®, to Optimize Wei
-
Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication: Hospitalized Adult Patients with Any Type of Viral Acute Respiratory Distress Syndrome (ARDS)
-
Veru to Participate in Fireside Chat at the 2023 Cantor Fitzgerald Global Healthcare Conference on September 28th, 2023
-
Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen Receptor Targeting Agonist, in AR+ ER+ HER2- Metastatic Breast Cancer
-
Veru to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 11th, 2023
-
Veru Reports Fiscal 2023 Third Quarter Financial Results
-
Veru to Report Fiscal 2023 Third Quarter Financial Results on August 10, 2023
-
Veru Inc.’s Oncology Drug Research Program Partner, The University of Tennessee Health Science Center, Awarded Two New Federal Grants
-
Veru Announces Appointment of Dr. Erik Swenson and Dr. Robert Schooley to its Infectious Disease Scientific Advisory Board
-
Veru to Present at the Jefferies Healthcare Conference
-
Veru Reports Fiscal 2023 Second Quarter Financial Results
-
Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS
-
Veru to Report Fiscal 2023 Second Quarter Financial Results on May 11, 2023
-
Veru Sells ENTADFI® Business for $20 Million Plus up to an Additional $80 Million from Sales Milestones
-
Veru Enters Into Supply Agreement with Afaxys to Expand Access to FC2 Female Condom® in U.S. Public Health Sector
-
Veru Announces Preclinical Study Results that Demonstrate Sabizabulin Inhibits Poxviruses
-
Veru Announces Preclinical Results from Expanded Sabizabulin Program into Influenza-Induced Severe Acute Respiratory Distress Syndrome and Provides Update on COVID-19 Program
-
Veru to Present at the Oppenheimer 33rd Annual Healthcare Conference
-
Veru Provides FDA Update on Request for Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for ARDS
-
Veru Reports Fiscal 2023 First Quarter Financial Results
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Generac, Veru, Gap, and Singularity and Encourages Investors to Contact the Firm
-
Veru to Report Fiscal 2023 First Quarter Financial Results on February 9, 2023
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Generac, Veru, Gap, and Singularity and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Generac, Veru, Gap, and Singularity and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Veru, Gap, Singularity, and F45 Training and Encourages Investors to Contact the Firm
-
Veru Announces Appointment of Dr. David D. Ho as Chairman of its Infectious Disease Scientific Advisory Board
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bird, Generac, Veru, and Gap and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Generac, Veru, Gap, and F45 Training and Encourages Investors to Contact the Firm
-
VERU ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Veru Inc. and Encourages Investors to Contact the Firm
-
VERU ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Veru Inc. and Encourages Investors to Contact the Firm
-
VERU ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Veru Inc. and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Generac, Veru, and F45 Training and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Generac, and Veru and Encourages Investors to Contact the Firm
-
Veru Reports Fiscal 2022 Fourth Quarter and Full Year Financial Results
-
Bragar Eagel & Squire, P.C. Is Investigating Veru, Twist, and Leidos and Encourages Investors to Contact the Firm
-
Veru to Report Fiscal 2022 Fourth Quarter and Full Year Financial Results on December 5, 2022
-
Bragar Eagel & Squire, P.C. Is Investigating Veru, Twist, Leidos, and DLocal and Encourages Investors to Contact the Firm
Back to VERU Stock Lookup
